Humanetics Corporation and researchers from the Armed Forces Radiobiology Research Institute (AFRRI) have partnered to secure $3 million in funding for the development of BIO 300. This medical countermeasure aims to protect military personnel and first responders from radiation exposure.

The funding will support testing a new formulation of BIO 300 compatible with auto-injectors, enabling self-administration. The military commonly uses auto-injectors to deliver emergency medications. This formulation complements existing oral formulations of BIO 300, which have undergone extensive testing and are in clinical trials.

AFRRI researchers initially identified BIO 300’s radioprotective properties. Humanetics holds an exclusive license to the drug and is leading its development for FDA approval. The company is also exploring its potential to reduce radiation-related side effects in cancer patients who undergo radiation therapy.

Ronald J. Zenk, President and CEO of Humanetics, emphasized the importance of safeguarding military and civilian personnel against radiation threats in the face of nuclear warfare concerns. He said, “Developing radioprotective drugs underscores our dedication to preparing for any scenario and ensuring our forces are protected against evolving modern conflict challenges.”

The DOD’s investment in BIO 300 reflects its commitment to protecting the armed forces and recognizes its potential to benefit civilian populations at risk of radiation exposure and improve the lives of cancer patients receiving radiation therapy. The initiative showcases the intersection of pharmaceutical innovation with national defense priorities and public health resilience.

Source link: http://www.businesswire.com/news/home/20240808093925/en/Uniformed-Services-University-Awards-Grant-to-Support-Continued-Collaboration-with-Humanetics-to-Develop-Radiation-Countermeasure

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.